US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

15.95

-0.6000-3.63%

Post-market: 16.260.3100+1.94%16:02 EST

Volume:38.05K

Turnover:631.12K

Market Cap:306.42M

PE:-0.68

High:17.75

Open:16.55

Low:15.72

Close:16.55

52wk High:30.00

52wk Low:7.65

Shares:19.21M

Float Shares:13.11M

Volume Ratio:2.78

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.5192

EPS(LYR):-26.2348

ROE:-76.59%

ROA:-25.39%

PB:1.03

PE(LYR):-0.61

Loading ...

Overview Company News Filings

Lyell Immunopharma Unveils Promising Phase 1/2 Data for Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma

Lyell Announces Two Oral Presentations From the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67TH Ash Annual Meeting and Exposition

THOMSON REUTERS

Lyell Immunopharma Inc - Appoints Lynn Seely as Interim CFO - SEC Filing

THOMSON REUTERS

Lyell Immunopharma Appoints Lynn Seely as Interim CFO and Veronica Sanchez Bulis as Principal Accounting Officer

Lyell Immunopharma Initiated at Buy by LUCID CAPITAL MARKETS

Lyell Immunopharma initiated with a Buy at Lucid Capital

Lyell Immunopharma Launches CFO Search After Newton Departs

Lyell Immunopharma CFO Resignation Announced

Lyell Immunopharma Inc - Charles Newton Resigns as CFO of Lyell Immunopharma - SEC Filing

THOMSON REUTERS

Lyell Immunopharma Begins Phase 3 Trial of LYL314 in Large B-Cell Lymphoma

MT Newswires Live

Lyell Immunopharma Initiates Phase 3 Trial for Innovative Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head Car T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

THOMSON REUTERS

Lyell Immunopharma to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Lyell Immunopharma's Chief Scientific Officer Gary K. Lee Reports Disposal of Common Shares

CFO Charles W. Newton Reports Disposal of Lyell Immunopharma Common Shares

Lyell Immunopharma Reports Q2 2025 Net Loss of $42.7M, Decrease from $45.8M in Q2 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Lyell Immunopharma Inc expected to post a loss of $3.58 a share - Earnings Preview

Lyell Immunopharma Inc. Files Initial Statement of Beneficial Ownership for ARCH Venture Fund XIII, L.P

Lyell Immunopharma Initiates Phase 3 Clinical Trial for LYL314 in Relapsed or Refractory Large B-Cell Lymphoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LYEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LYEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYEL\",,,,,undefined,":{"symbol":"LYEL","market":"US","secType":"STK","nameCN":"Lyell Immunopharma, Inc.","latestPrice":15.95,"timestamp":1762290000000,"preClose":16.55,"halted":0,"volume":38050,"hourTrading":{"tag":"盘后","latestPrice":16.26,"preClose":15.95,"latestTime":"16:02 EST","volume":52,"amount":834.049996,"timestamp":1762290133974},"delay":0,"floatShares":13109121,"shares":19211202,"eps":-23.519178,"marketStatus":"Post-Mkt","change":-0.6,"latestTime":"11-04 18:46:55 EST","open":16.55,"high":17.75,"low":15.72,"amount":631123.496138,"amplitude":0.122659,"askPrice":17.75,"askSize":10,"bidPrice":15.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-23.519178,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762304400000},"marketStatusCode":4,"adr":0,"listingDate":1623902400000,"exchange":"NASDAQ","adjPreClose":16.55,"preHourTrading":{"tag":"盘前","latestPrice":16.45,"preClose":16.55,"latestTime":"09:11 EST","volume":1400,"amount":23030,"timestamp":1762265486095},"postHourTrading":{"tag":"盘后","latestPrice":16.26,"preClose":15.95,"latestTime":"16:02 EST","volume":52,"amount":834.049996,"timestamp":1762290133974},"volumeRatio":2.781433,"impliedVol":0.6332,"impliedVolPercentile":0.3133},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYEL\",,,,,undefined,":{"symbol":"LYEL","floatShares":13109121,"roa":"-25.39%","roe":"-76.59%","lyrEps":-26.234817,"volumeRatio":2.781433,"shares":19211202,"dividePrice":0,"high":17.75,"amplitude":0.122659,"preClose":16.55,"low":15.72,"week52Low":7.65,"pbRate":"1.03","psRate":"5106.98","week52High":29.998,"institutionHeld":0,"latestPrice":15.95,"committee":0.818182,"eps":-23.519178,"divideRate":0,"volume":38050,"delay":0,"ttmEps":-23.519178,"open":16.55,"prevYearClose":12.8,"prevWeekClose":16.66,"prevMonthClose":16.66,"prevQuarterClose":16.24,"fiveDayClose":16.71,"twentyDayClose":17.69,"sixtyDayClose":10.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LYEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"LYEL","fiscalQuarterEnding":"2025/06","expectedEps":-3.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-2.89},{"market":"US","date":"2025-06-02","symbol":"LYEL","defaultRemindTime":1748871000000,"type":"split","dateTimestamp":1748836800000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-05-13","symbol":"LYEL","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2021-08-12","symbol":"LYEL","fiscalQuarterEnding":"2021/06","expectedEps":-1.54,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-1.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LYEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LYEL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.3333,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.3333,"analysts":3,"updateTime":1759122000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LYEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LYEL","date":"2025-11-03","current":-0.754703,"percent":0.820298,"low":-22.356321,"twenty":-7.068343,"median":-2.876154,"eighty":-1.039259,"high":-0.344317,"avg":-4.65526,"sd":4.792752,"marketCap":320058625},"quantilePoints":[{"date":"2021-06-18","current":-16.694562,"twenty":-17.926867,"median":-17.666247,"eighty":-17.121201,"marketCap":3844340254},{"date":"2021-06-25","current":-16.478151,"twenty":-17.614123,"median":-17.106773,"eighty":-16.61212,"marketCap":3794506214},{"date":"2021-07-02","current":-16.519372,"twenty":-17.263414,"median":-16.936736,"eighty":-16.511128,"marketCap":3803998412},{"date":"2021-07-09","current":-16.364793,"twenty":-17.143872,"median":-16.715173,"eighty":-16.410136,"marketCap":3768402669},{"date":"2021-07-16","current":-17.426237,"twenty":-17.174788,"median":-16.735783,"eighty":-16.482273,"marketCap":4012826772},{"date":"2021-07-23","current":-14.870526,"twenty":-17.174788,"median":-16.725478,"eighty":-16.253496,"marketCap":3424310486},{"date":"2021-07-30","current":-14.942663,"twenty":-17.143872,"median":-16.560593,"eighty":-15.769148,"marketCap":3440921833},{"date":"2021-08-06","current":-16.117466,"twenty":-17.090285,"median":-16.509067,"eighty":-15.769148,"marketCap":3711449480},{"date":"2021-08-13","current":-18.445521,"twenty":-17.143872,"median":-16.498762,"eighty":-15.358997,"marketCap":3545487430},{"date":"2021-08-20","current":-18.856529,"twenty":-17.417993,"median":-16.627578,"eighty":-15.57953,"marketCap":3624488838},{"date":"2021-08-27","current":-20.214099,"twenty":-17.926867,"median":-16.735783,"eighty":-15.769148,"marketCap":3885432883},{"date":"2021-09-03","current":-20.525469,"twenty":-18.490358,"median":-16.802768,"eighty":-15.903116,"marketCap":3945282434},{"date":"2021-09-10","current":-22.356321,"twenty":-19.232663,"median":-17.003721,"eighty":-15.991741,"marketCap":4297197797},{"date":"2021-09-17","current":-14.709089,"twenty":-19.232663,"median":-16.952194,"eighty":-15.876323,"marketCap":2827292812},{"date":"2021-09-24","current":-15.294463,"twenty":-19.005986,"median":-16.777005,"eighty":-15.276839,"marketCap":2939809969},{"date":"2021-10-01","current":-16.552396,"twenty":-18.789273,"median":-16.78731,"eighty":-15.333339,"marketCap":3181602157},{"date":"2021-10-08","current":-16.116478,"twenty":-18.505304,"median":-16.725478,"eighty":-15.276839,"marketCap":3097812785},{"date":"2021-10-15","current":-16.539941,"twenty":-18.44303,"median":-16.694562,"eighty":-15.276839,"marketCap":3179208175},{"date":"2021-10-22","current":-17.175134,"twenty":-18.41563,"median":-16.725478,"eighty":-15.333339,"marketCap":3301301260},{"date":"2021-10-29","current":-17.361956,"twenty":-18.41563,"median":-16.78731,"eighty":-15.492314,"marketCap":3337210991},{"date":"2021-11-05","current":-17.212499,"twenty":-18.44303,"median":-16.889297,"eighty":-15.548067,"marketCap":3308483206},{"date":"2021-11-12","current":-13.33676,"twenty":-18.41563,"median":-16.78731,"eighty":-15.276839,"marketCap":2738970350},{"date":"2021-11-19","current":-12.657627,"twenty":-18.330937,"median":-16.725478,"eighty":-15.027931,"marketCap":2599496882},{"date":"2021-11-26","current":-10.90125,"twenty":-18.271154,"median":-16.627578,"eighty":-14.942663,"marketCap":2238789637},{"date":"2021-12-03","current":-10.409464,"twenty":-18.134152,"median":-16.539941,"eighty":-14.709089,"marketCap":2137791608},{"date":"2021-12-10","current":-10.948086,"twenty":-18.109242,"median":-16.493609,"eighty":-14.3479,"marketCap":2248408496},{"date":"2021-12-17","current":-9.765459,"twenty":-18.071878,"median":-16.415393,"eighty":-13.737616,"marketCap":2005532284},{"date":"2021-12-23","current":-9.613239,"twenty":-18.012095,"median":-16.364793,"eighty":-12.985484,"marketCap":1974270990},{"date":"2021-12-31","current":-9.062908,"twenty":-17.940923,"median":-16.245376,"eighty":-12.198627,"marketCap":1861249386},{"date":"2022-01-07","current":-7.470459,"twenty":-17.926867,"median":-16.141388,"eighty":-11.395378,"marketCap":1534208150},{"date":"2022-01-14","current":-7.072347,"twenty":-17.903382,"median":-16.080903,"eighty":-10.997265,"marketCap":1452447841},{"date":"2022-01-21","current":-6.123903,"twenty":-17.830255,"median":-16.014551,"eighty":-10.929352,"marketCap":1257665929},{"date":"2022-01-28","current":-6.147321,"twenty":-17.680798,"median":-15.983497,"eighty":-10.514847,"marketCap":1262475359},{"date":"2022-02-04","current":-6.627398,"twenty":-17.596106,"median":-15.610877,"eighty":-9.704571,"marketCap":1361068673},{"date":"2022-02-11","current":-7.072347,"twenty":-17.556251,"median":-15.294463,"eighty":-9.011387,"marketCap":1452447841},{"date":"2022-02-18","current":-7.013801,"twenty":-17.470271,"median":-15.182102,"eighty":-8.728025,"marketCap":1440424267},{"date":"2022-02-25","current":-8.102755,"twenty":-17.425434,"median":-15.057823,"eighty":-8.163643,"marketCap":1664062759},{"date":"2022-03-04","current":-7.634387,"twenty":-17.416789,"median":-14.958184,"eighty":-7.964586,"marketCap":1567874160},{"date":"2022-03-11","current":-7.669515,"twenty":-17.388159,"median":-14.860221,"eighty":-7.915408,"marketCap":1575088305},{"date":"2022-03-18","current":-7.013801,"twenty":-17.351992,"median":-14.709089,"eighty":-7.723377,"marketCap":1440424267},{"date":"2022-03-25","current":-5.971683,"twenty":-17.3221,"median":-14.403329,"eighty":-7.58755,"marketCap":1226404634},{"date":"2022-04-01","current":-5.20082,"twenty":-17.2947,"median":-14.061441,"eighty":-7.470459,"marketCap":1301343937},{"date":"2022-04-08","current":-5.288147,"twenty":-17.257336,"median":-13.830028,"eighty":-7.346342,"marketCap":1323194861},{"date":"2022-04-14","current":-5.229929,"twenty":-17.211964,"median":-13.518506,"eighty":-7.16602,"marketCap":1308627578},{"date":"2022-04-22","current":-5.045571,"twenty":-17.203643,"median":-12.938648,"eighty":-7.018485,"marketCap":1262497849},{"date":"2022-04-29","current":-4.97765,"twenty":-17.178155,"median":-12.487844,"eighty":-6.955255,"marketCap":1245502686},{"date":"2022-05-06","current":-5.152305,"twenty":-17.173828,"median":-11.627219,"eighty":-6.641449,"marketCap":1289204534},{"date":"2022-05-13","current":-3.729604,"twenty":-17.156239,"median":-11.381327,"eighty":-6.524357,"marketCap":982079216},{"date":"2022-05-20","current":-3.841772,"twenty":-17.098529,"median":-11.135433,"eighty":-6.360429,"marketCap":1011615433},{"date":"2022-05-27","current":-4.056762,"twenty":-17.063491,"median":-10.953941,"eighty":-6.039597,"marketCap":1068226516},{"date":"2022-06-03","current":-4.711078,"twenty":-17.055247,"median":-10.924668,"eighty":-5.971683,"marketCap":1240521115},{"date":"2022-06-10","current":-4.767162,"twenty":-16.952194,"median":-10.74903,"eighty":-5.501614,"marketCap":1255289224},{"date":"2022-06-17","current":-5.103668,"twenty":-16.826401,"median":-10.444591,"eighty":-5.278444,"marketCap":1343897875},{"date":"2022-06-24","current":-6.225353,"twenty":-16.81986,"median":-9.993788,"eighty":-5.286206,"marketCap":1639260045},{"date":"2022-07-01","current":-5.599079,"twenty":-16.793493,"median":-9.191709,"eighty":-5.303672,"marketCap":1474349500},{"date":"2022-07-08","current":-6.281438,"twenty":-16.774943,"median":-9.016071,"eighty":-5.331041,"marketCap":1654028154},{"date":"2022-07-15","current":-5.514953,"twenty":-16.748149,"median":-8.822869,"eighty":-5.314216,"marketCap":1452197337},{"date":"2022-07-22","current":-5.3467,"twenty":-16.723417,"median":-8.664796,"eighty":-5.314216,"marketCap":1407893012},{"date":"2022-07-29","current":-5.206489,"twenty":-16.702806,"median":-8.301811,"eighty":-5.299791,"marketCap":1370972740},{"date":"2022-08-05","current":-7.600529,"twenty":-16.614181,"median":-8.044209,"eighty":-5.299791,"marketCap":1801690265},{"date":"2022-08-12","current":-7.642348,"twenty":-16.555675,"median":-7.991734,"eighty":-5.314216,"marketCap":1811603279},{"date":"2022-08-19","current":-7.360072,"twenty":-16.544923,"median":-7.950535,"eighty":-5.335483,"marketCap":1744690435},{"date":"2022-08-26","current":-6.575974,"twenty":-16.5276,"median":-7.950535,"eighty":-5.3467,"marketCap":1558821426},{"date":"2022-09-02","current":-7.192798,"twenty":-16.507006,"median":-7.89199,"eighty":-5.375608,"marketCap":1705038380},{"date":"2022-09-09","current":-7.935078,"twenty":-16.49464,"median":-7.88028,"eighty":-5.416736,"marketCap":1880994376},{"date":"2022-09-16","current":-7.516892,"twenty":-16.484334,"median":-7.897852,"eighty":-5.449521,"marketCap":1781864237},{"date":"2022-09-23","current":-6.670066,"twenty":-16.453048,"median":-7.861895,"eighty":-5.45326,"marketCap":1581125707},{"date":"2022-09-30","current":-7.663257,"twenty":-16.400447,"median":-7.848297,"eighty":-5.462607,"marketCap":1816559786},{"date":"2022-10-07","current":-7.391436,"twenty":-16.372735,"median":-7.851441,"eighty":-5.468216,"marketCap":1752125196},{"date":"2022-10-14","current":-6.83734,"twenty":-16.35016,"median":-7.81485,"eighty":-5.468216,"marketCap":1620777762},{"date":"2022-10-21","current":-6.847795,"twenty":-16.313264,"median":-7.751479,"eighty":-5.477563,"marketCap":1623256016},{"date":"2022-10-28","current":-6.38779,"twenty":-16.25447,"median":-7.704859,"eighty":-5.495596,"marketCap":1514212864},{"date":"2022-11-04","current":-5.93824,"twenty":-16.191664,"median":-7.669515,"eighty":-5.50695,"marketCap":1407647965},{"date":"2022-11-11","current":-4.370461,"twenty":-16.164134,"median":-7.652802,"eighty":-5.468216,"marketCap":1129445090},{"date":"2022-11-18","current":-4.235391,"twenty":-16.131819,"median":-7.634387,"eighty":-5.449521,"marketCap":1094539502},{"date":"2022-11-25","current":-4.013492,"twenty":-16.117268,"median":-7.600529,"eighty":-5.3467,"marketCap":1037194608},{"date":"2022-12-02","current":-3.88807,"twenty":-16.102248,"median":-7.558277,"eighty":-5.287232,"marketCap":1004782276},{"date":"2022-12-09","current":-3.38156,"twenty":-16.041207,"median":-7.516892,"eighty":-5.259745,"marketCap":873886322},{"date":"2022-12-16","current":-3.116245,"twenty":-16.020651,"median":-7.489702,"eighty":-5.234588,"marketCap":805321775},{"date":"2022-12-23","current":-2.942584,"twenty":-16.001894,"median":-7.470459,"eighty":-5.20082,"marketCap":760443162},{"date":"2022-12-30","current":-3.347792,"twenty":-15.991931,"median":-7.407118,"eighty":-5.178447,"marketCap":865159925},{"date":"2023-01-06","current":-3.154836,"twenty":-15.985184,"median":-7.391436,"eighty":-5.132899,"marketCap":815294800},{"date":"2023-01-13","current":-3.116245,"twenty":-15.876323,"median":-7.35672,"eighty":-5.045571,"marketCap":805321775},{"date":"2023-01-20","current":-2.884697,"twenty":-15.769148,"median":-7.319501,"eighty":-5.004818,"marketCap":745483624},{"date":"2023-01-27","current":-3.222371,"twenty":-15.58994,"median":-7.255526,"eighty":-4.957491,"marketCap":832747594},{"date":"2023-02-03","current":-3.280258,"twenty":-15.495784,"median":-7.203252,"eighty":-4.852942,"marketCap":847707131},{"date":"2023-02-10","current":-2.759276,"twenty":-15.372215,"median":-7.16602,"eighty":-4.658733,"marketCap":713071293},{"date":"2023-02-17","current":-2.51808,"twenty":-15.281245,"median":-7.127136,"eighty":-4.40097,"marketCap":650739886},{"date":"2023-02-24","current":-2.054985,"twenty":-15.24139,"median":-7.072347,"eighty":-4.297137,"marketCap":531063585},{"date":"2023-03-03","current":-3.026095,"twenty":-15.184647,"median":-7.037219,"eighty":-4.234774,"marketCap":554132528},{"date":"2023-03-10","current":-2.712581,"twenty":-15.144685,"median":-7.009208,"eighty":-4.144702,"marketCap":496722401},{"date":"2023-03-17","current":-2.903416,"twenty":-15.067786,"median":-7.002092,"eighty":-4.0308,"marketCap":531667696},{"date":"2023-03-24","current":-2.739843,"twenty":-15.002478,"median":-6.947944,"eighty":-3.941641,"marketCap":501714586},{"date":"2023-03-31","current":-3.21693,"twenty":-14.979788,"median":-6.847795,"eighty":-3.877116,"marketCap":589077822},{"date":"2023-04-06","current":-3.503182,"twenty":-14.95508,"median":-6.791326,"eighty":-3.841772,"marketCap":641495764},{"date":"2023-04-14","current":-3.775804,"twenty":-14.928236,"median":-6.698816,"eighty":-3.793887,"marketCap":691417614},{"date":"2023-04-21","current":-3.053357,"twenty":-14.866404,"median":-6.650816,"eighty":-3.755799,"marketCap":559124713},{"date":"2023-04-28","current":-2.658057,"twenty":-14.849916,"median":-6.633253,"eighty":-3.642559,"marketCap":486738031},{"date":"2023-05-05","current":-3.298717,"twenty":-14.821751,"median":-6.575974,"eighty":-3.508635,"marketCap":604054377},{"date":"2023-05-12","current":-3.457401,"twenty":-14.671725,"median":-6.54314,"eighty":-3.473214,"marketCap":629015302},{"date":"2023-05-19","current":-3.457401,"twenty":-14.499848,"median":-6.38779,"eighty":-3.464474,"marketCap":629015302},{"date":"2023-05-26","current":-3.896436,"twenty":-14.407436,"median":-6.36768,"eighty":-3.473214,"marketCap":708890261},{"date":"2023-06-02","current":-4.568708,"twenty":-14.396483,"median":-6.357152,"eighty":-3.473214,"marketCap":831198792},{"date":"2023-06-09","current":-4.225712,"twenty":-14.3479,"median":-6.281438,"eighty":-3.503182,"marketCap":768796480},{"date":"2023-06-16","current":-5.29586,"twenty":-14.061441,"median":-6.257519,"eighty":-3.503182,"marketCap":963491693},{"date":"2023-06-23","current":-4.513829,"twenty":-14.001658,"median":-6.228162,"eighty":-3.524992,"marketCap":821214422},{"date":"2023-06-30","current":-4.294311,"twenty":-13.948149,"median":-6.173469,"eighty":-3.546802,"marketCap":781276943},{"date":"2023-07-07","current":-3.930735,"twenty":-13.84851,"median":-6.1421,"eighty":-3.566976,"marketCap":715130492},{"date":"2023-07-14","current":-4.294311,"twenty":-13.72267,"median":-6.113185,"eighty":-3.59924,"marketCap":781276943},{"date":"2023-07-21","current":-4.253152,"twenty":-13.554855,"median":-6.089817,"eighty":-3.631866,"marketCap":773788665},{"date":"2023-07-27","current":-4.253152,"twenty":-13.33676,"median":-6.029058,"eighty":-3.639493,"marketCap":773788665},{"date":"2023-08-03","current":-3.622039,"twenty":-13.065106,"median":-5.995102,"eighty":-3.636951,"marketCap":658968412},{"date":"2023-08-11","current":-2.767887,"twenty":-12.950357,"median":-5.958308,"eighty":-3.576245,"marketCap":579872363},{"date":"2023-08-18","current":-2.684012,"twenty":-12.835607,"median":-5.924847,"eighty":-3.497188,"marketCap":562300473},{"date":"2023-08-25","current":-2.67203,"twenty":-12.688071,"median":-5.837903,"eighty":-3.457401,"marketCap":559790203},{"date":"2023-09-01","current":-2.863745,"twenty":-12.385974,"median":-5.708238,"eighty":-3.438793,"marketCap":599954522},{"date":"2023-09-08","current":-2.34851,"twenty":-11.95976,"median":-5.599079,"eighty":-3.385905,"marketCap":492012914},{"date":"2023-09-15","current":-2.090893,"twenty":-11.683423,"median":-5.5243,"eighty":-3.342883,"marketCap":438042109},{"date":"2023-09-22","current":-1.773365,"twenty":-11.566331,"median":-5.496599,"eighty":-3.255097,"marketCap":371519955},{"date":"2023-09-29","current":-1.881205,"twenty":-11.446898,"median":-5.468216,"eighty":-3.219106,"marketCap":394112385},{"date":"2023-10-06","current":-1.785347,"twenty":-11.38601,"median":-5.454194,"eighty":-3.197376,"marketCap":374030225},{"date":"2023-10-13","current":-1.869223,"twenty":-11.287653,"median":-5.39488,"eighty":-3.168343,"marketCap":391602115},{"date":"2023-10-20","current":-1.893187,"twenty":-11.163535,"median":-5.332679,"eighty":-3.158301,"marketCap":396622655},{"date":"2023-10-27","current":-1.953098,"twenty":-11.1448,"median":-5.313106,"eighty":-3.154836,"marketCap":409174005},{"date":"2023-11-03","current":-2.396439,"twenty":-11.032392,"median":-5.288147,"eighty":-3.144199,"marketCap":502053994},{"date":"2023-11-10","current":-2.901609,"twenty":-10.969163,"median":-5.278444,"eighty":-3.116245,"marketCap":551593039},{"date":"2023-11-17","current":-2.47763,"twenty":-10.950428,"median":-5.259038,"eighty":-3.07552,"marketCap":470994970},{"date":"2023-11-24","current":-2.225892,"twenty":-10.948086,"median":-5.259038,"eighty":-3.034274,"marketCap":423139866},{"date":"2023-12-01","current":-2.292139,"twenty":-10.919984,"median":-5.220226,"eighty":-2.985202,"marketCap":435733314},{"date":"2023-12-08","current":-2.570375,"twenty":-10.859097,"median":-5.20082,"eighty":-2.966092,"marketCap":488625797},{"date":"2023-12-15","current":-2.67637,"twenty":-10.781816,"median":-5.191971,"eighty":-2.932936,"marketCap":508775315},{"date":"2023-12-22","current":-2.649872,"twenty":-10.622571,"median":-5.162008,"eighty":-2.925226,"marketCap":503737936},{"date":"2023-12-29","current":-2.795615,"twenty":-10.526556,"median":-5.142602,"eighty":-2.903531,"marketCap":531443522},{"date":"2024-01-05","current":-2.636622,"twenty":-10.491428,"median":-5.132899,"eighty":-2.892415,"marketCap":501219246},{"date":"2024-01-12","current":-2.914859,"twenty":-10.423515,"median":-5.074619,"eighty":-2.876069,"marketCap":554111729},{"date":"2024-01-19","current":-2.610123,"twenty":-10.297056,"median":-5.040719,"eighty":-2.870527,"marketCap":496181866},{"date":"2024-01-26","current":-2.769116,"twenty":-9.948122,"median":-4.987353,"eighty":-2.82681,"marketCap":526406143},{"date":"2024-02-02","current":-2.451131,"twenty":-9.674127,"median":-4.970553,"eighty":-2.813035,"marketCap":465957590},{"date":"2024-02-09","current":-2.26564,"twenty":-9.360321,"median":-4.907373,"eighty":-2.806332,"marketCap":430695935},{"date":"2024-02-16","current":-2.517378,"twenty":-9.114428,"median":-4.849986,"eighty":-2.790315,"marketCap":478551039},{"date":"2024-02-23","current":-3.232843,"twenty":-9.044173,"median":-4.776239,"eighty":-2.787665,"marketCap":614560281},{"date":"2024-03-01","current":-3.162234,"twenty":-9.011387,"median":-4.733346,"eighty":-2.795615,"marketCap":741961228},{"date":"2024-03-08","current":-2.729051,"twenty":-8.93879,"median":-4.699047,"eighty":-2.787665,"marketCap":640322703},{"date":"2024-03-15","current":-2.393334,"twenty":-8.826382,"median":-4.580215,"eighty":-2.779437,"marketCap":561552847},{"date":"2024-03-22","current":-2.209232,"twenty":-8.791255,"median":-4.524152,"eighty":-2.767887,"marketCap":518356474},{"date":"2024-03-28","current":-2.209232,"twenty":-8.749102,"median":-4.472669,"eighty":-2.760842,"marketCap":518356474},{"date":"2024-04-05","current":-2.26338,"twenty":-8.661036,"median":-4.437996,"eighty":-2.746312,"marketCap":531061289},{"date":"2024-04-12","current":-2.880665,"twenty":-8.612285,"median":-4.40407,"eighty":-2.740398,"marketCap":675896187},{"date":"2024-04-19","current":-2.523289,"twenty":-8.473521,"median":-4.37663,"eighty":-2.729051,"marketCap":592044404},{"date":"2024-04-26","current":-2.390385,"twenty":-8.435978,"median":-4.373545,"eighty":-2.713288,"marketCap":560860924},{"date":"2024-05-03","current":-2.607693,"twenty":-8.343298,"median":-4.308031,"eighty":-2.687454,"marketCap":611848281},{"date":"2024-05-10","current":-2.992192,"twenty":-8.3219,"median":-4.294311,"eighty":-2.687454,"marketCap":683237114},{"date":"2024-05-17","current":-3.103841,"twenty":-8.319809,"median":-4.254687,"eighty":-2.687454,"marketCap":708731037},{"date":"2024-05-24","current":-3.025687,"twenty":-8.307263,"median":-4.253152,"eighty":-2.697369,"marketCap":690885291},{"date":"2024-05-31","current":-2.969862,"twenty":-8.290536,"median":-4.253152,"eighty":-2.702869,"marketCap":678138330},{"date":"2024-06-07","current":-2.768894,"twenty":-8.254974,"median":-4.239432,"eighty":-2.702869,"marketCap":632249270},{"date":"2024-06-14","current":-2.891708,"twenty":-8.249968,"median":-4.234362,"eighty":-2.702869,"marketCap":660292584},{"date":"2024-06-21","current":-2.322298,"twenty":-8.16114,"median":-4.225712,"eighty":-2.684796,"marketCap":530273581},{"date":"2024-06-28","current":-1.540756,"twenty":-8.102755,"median":-4.225015,"eighty":-2.684012,"marketCap":351816126},{"date":"2024-07-05","current":-1.685899,"twenty":-8.085705,"median":-4.184553,"eighty":-2.678934,"marketCap":384958225},{"date":"2024-07-12","current":-1.898032,"twenty":-8.051656,"median":-4.129469,"eighty":-2.657094,"marketCap":433396677},{"date":"2024-07-15","current":-1.909197,"twenty":-8.044209,"median":-4.129265,"eighty":-2.653244,"marketCap":435946069},{"date":"2024-08-02","current":-1.674734,"twenty":-8.037183,"median":-4.122609,"eighty":-2.651573,"marketCap":382408833},{"date":"2024-08-09","current":-1.826341,"twenty":-8.006826,"median":-4.102234,"eighty":-2.638911,"marketCap":384004669},{"date":"2024-08-16","current":-1.528039,"twenty":-7.995377,"median":-4.066555,"eighty":-2.636083,"marketCap":321283906},{"date":"2024-08-23","current":-1.765463,"twenty":-7.98391,"median":-4.033634,"eighty":-2.631614,"marketCap":371204513},{"date":"2024-08-30","current":-1.777639,"twenty":-7.976897,"median":-4.016703,"eighty":-2.61181,"marketCap":373764544},{"date":"2024-09-06","current":-1.558478,"twenty":-7.976897,"median":-3.997437,"eighty":-2.600136,"marketCap":327683984},{"date":"2024-09-13","current":-1.400195,"twenty":-7.950535,"median":-3.965035,"eighty":-2.577437,"marketCap":294403579},{"date":"2024-09-20","current":-1.899395,"twenty":-7.950535,"median":-3.965035,"eighty":-2.570375,"marketCap":399364856},{"date":"2024-09-27","current":-1.850692,"twenty":-7.950535,"median":-3.930735,"eighty":-2.557126,"marketCap":389124731},{"date":"2024-10-04","current":-1.448897,"twenty":-7.935078,"median":-3.892473,"eighty":-2.543877,"marketCap":304643704},{"date":"2024-10-11","current":-1.327141,"twenty":-7.903714,"median":-3.88807,"eighty":-2.530627,"marketCap":279043393},{"date":"2024-10-18","current":-1.436722,"twenty":-7.89199,"median":-3.841772,"eighty":-2.517378,"marketCap":302083673},{"date":"2024-10-25","current":-1.327141,"twenty":-7.88028,"median":-3.830328,"eighty":-2.499039,"marketCap":279043393},{"date":"2024-10-31","current":-1.045032,"twenty":-7.865572,"median":-3.823077,"eighty":-2.47498,"marketCap":219727471},{"date":"2024-11-08","current":-1.531082,"twenty":-7.853532,"median":-3.797329,"eighty":-2.424262,"marketCap":312323797},{"date":"2024-11-15","current":-1.505683,"twenty":-7.846411,"median":-3.786677,"eighty":-2.411954,"marketCap":307142675},{"date":"2024-11-22","current":-1.254644,"twenty":-7.841819,"median":-3.775936,"eighty":-2.392744,"marketCap":255933614},{"date":"2024-11-29","current":-1.293655,"twenty":-7.809622,"median":-3.759997,"eighty":-2.378477,"marketCap":263891402},{"date":"2024-12-06","current":-1.259298,"twenty":-7.769895,"median":-3.714409,"eighty":-2.359862,"marketCap":256882964},{"date":"2024-12-13","current":-1.040564,"twenty":-7.753827,"median":-3.659012,"eighty":-2.350461,"marketCap":212263510},{"date":"2024-12-20","current":-0.877402,"twenty":-7.748728,"median":-3.626782,"eighty":-2.335862,"marketCap":178980413},{"date":"2024-12-27","current":-0.889311,"twenty":-7.730167,"median":-3.608319,"eighty":-2.323428,"marketCap":181409632},{"date":"2025-01-03","current":-0.882877,"twenty":-7.704989,"median":-3.557707,"eighty":-2.2786,"marketCap":180097296},{"date":"2025-01-10","current":-0.933392,"twenty":-7.704643,"median":-3.503182,"eighty":-2.26338,"marketCap":190401751},{"date":"2025-01-17","current":-0.80048,"twenty":-7.694621,"median":-3.473214,"eighty":-2.228646,"marketCap":163289149},{"date":"2025-01-24","current":-0.836716,"twenty":-7.674536,"median":-3.466811,"eighty":-2.211961,"marketCap":170680839},{"date":"2025-01-31","current":-0.835284,"twenty":-7.664509,"median":-3.457401,"eighty":-2.190367,"marketCap":170388677},{"date":"2025-02-07","current":-0.846455,"twenty":-7.663257,"median":-3.446877,"eighty":-2.138425,"marketCap":172667538},{"date":"2025-02-14","current":-0.833565,"twenty":-7.64653,"median":-3.402521,"eighty":-2.079975,"marketCap":170038083},{"date":"2025-02-21","current":-0.94528,"twenty":-7.642348,"median":-3.38156,"eighty":-2.054451,"marketCap":192826692},{"date":"2025-02-28","current":-1.020902,"twenty":-7.637571,"median":-3.343701,"eighty":-1.975864,"marketCap":208252828},{"date":"2025-03-07","current":-1.040381,"twenty":-7.627362,"median":-3.298717,"eighty":-1.933206,"marketCap":212226226},{"date":"2025-03-14","current":-0.521867,"twenty":-7.609389,"median":-3.265577,"eighty":-1.89885,"marketCap":178997262},{"date":"2025-03-21","current":-0.459033,"twenty":-7.587984,"median":-3.241666,"eighty":-1.893187,"marketCap":157445555},{"date":"2025-03-28","current":-0.510936,"twenty":-7.570327,"median":-3.226697,"eighty":-1.876412,"marketCap":175247856},{"date":"2025-04-04","current":-0.400244,"twenty":-7.557107,"median":-3.21693,"eighty":-1.854621,"marketCap":137281423},{"date":"2025-04-11","current":-0.357121,"twenty":-7.549923,"median":-3.198363,"eighty":-1.833647,"marketCap":122490457},{"date":"2025-04-17","current":-0.377865,"twenty":-7.53571,"median":-3.1819,"eighty":-1.804679,"marketCap":129605473},{"date":"2025-04-25","current":-0.401966,"twenty":-7.516892,"median":-3.166597,"eighty":-1.777639,"marketCap":137871881},{"date":"2025-05-02","current":-0.404697,"twenty":-7.507686,"median":-3.164484,"eighty":-1.775075,"marketCap":138808651},{"date":"2025-05-09","current":-0.368533,"twenty":-7.490537,"median":-3.162234,"eighty":-1.765463,"marketCap":126404474},{"date":"2025-05-16","current":-0.354647,"twenty":-7.4795,"median":-3.154836,"eighty":-1.754194,"marketCap":118637096},{"date":"2025-05-23","current":-0.372922,"twenty":-7.470459,"median":-3.154836,"eighty":-1.730229,"marketCap":124750584},{"date":"2025-05-30","current":-0.355548,"twenty":-7.461092,"median":-3.125893,"eighty":-1.710392,"marketCap":118938486},{"date":"2025-06-06","current":-0.507293,"twenty":-7.420321,"median":-3.116245,"eighty":-1.685899,"marketCap":169700573},{"date":"2025-06-13","current":-0.431155,"twenty":-7.403982,"median":-3.113599,"eighty":-1.670898,"marketCap":144230679},{"date":"2025-06-20","current":-0.424072,"twenty":-7.391436,"median":-3.092676,"eighty":-1.665525,"marketCap":141861387},{"date":"2025-06-27","current":-0.403709,"twenty":-7.391436,"median":-3.084406,"eighty":-1.652405,"marketCap":135049671},{"date":"2025-07-03","current":-0.428941,"twenty":-7.389083,"median":-3.074,"eighty":-1.61891,"marketCap":143490275},{"date":"2025-07-11","current":-0.432483,"twenty":-7.365757,"median":-3.059181,"eighty":-1.558478,"marketCap":144674922},{"date":"2025-07-18","current":-0.421416,"twenty":-7.354708,"median":-3.044181,"eighty":-1.530473,"marketCap":140972902},{"date":"2025-07-25","current":-0.460813,"twenty":-7.344,"median":-3.026095,"eighty":-1.517452,"marketCap":154152091},{"date":"2025-08-01","current":-0.523591,"twenty":-7.306207,"median":-3.009843,"eighty":-1.505683,"marketCap":175152551},{"date":"2025-08-08","current":-0.52307,"twenty":-7.288981,"median":-2.992192,"eighty":-1.485424,"marketCap":174978334},{"date":"2025-08-15","current":-0.623761,"twenty":-7.261799,"median":-2.985202,"eighty":-1.446462,"marketCap":206712533},{"date":"2025-08-22","current":-0.617384,"twenty":-7.230435,"median":-2.981027,"eighty":-1.424546,"marketCap":204599301},{"date":"2025-08-29","current":-0.643471,"twenty":-7.215798,"median":-2.963901,"eighty":-1.400195,"marketCap":213244342},{"date":"2025-09-05","current":-0.679413,"twenty":-7.201162,"median":-2.949882,"eighty":-1.390455,"marketCap":225155287},{"date":"2025-09-12","current":-0.771006,"twenty":-7.186525,"median":-2.941357,"eighty":-1.366748,"marketCap":255508986},{"date":"2025-09-19","current":-0.732745,"twenty":-7.172549,"median":-2.932936,"eighty":-1.322271,"marketCap":242829593},{"date":"2025-09-26","current":-0.737383,"twenty":-7.16602,"median":-2.930678,"eighty":-1.292013,"marketCap":244366489},{"date":"2025-10-03","current":-0.916511,"twenty":-7.16602,"median":-2.914448,"eighty":-1.257436,"marketCap":303729103},{"date":"2025-10-10","current":-1.093901,"twenty":-7.119359,"median":-2.903993,"eighty":-1.235371,"marketCap":362515381},{"date":"2025-10-17","current":-0.985496,"twenty":-7.078709,"median":-2.897977,"eighty":-1.135254,"marketCap":326590434},{"date":"2025-10-24","current":-1.062017,"twenty":-7.072347,"median":-2.884697,"eighty":-1.060626,"marketCap":351949220},{"date":"2025-10-31","current":-0.95825,"twenty":-7.069344,"median":-2.87841,"eighty":-1.040491,"marketCap":317561169},{"date":"2025-11-03","current":-0.965786,"twenty":-7.068343,"median":-2.876154,"eighty":-1.039259,"marketCap":320058625}],"updateTime":1762279112585},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LYEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580219800","title":"Lyell Immunopharma Unveils Promising Phase 1/2 Data for Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219800","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219800?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:00","pubTimestamp":1762178423,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Unveils Promising Phase 1/2 Data for Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6Zcjdl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","LYEL","LU2210149790.SGD","BK4505","IE00BGHQF748.EUR","BK4585","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4539","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2580219860","title":"Lyell Announces Two Oral Presentations From the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67TH Ash Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219860?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:00","pubTimestamp":1762178401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA53GLNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4539","BK4139","LYEL"],"gpt_icon":0},{"id":"2580157382","title":"Lyell Immunopharma Inc - Appoints Lynn Seely as Interim CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580157382","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580157382?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:33","pubTimestamp":1762176787,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4539","BK4139","LYEL"],"gpt_icon":0},{"id":"2580621527","title":"Lyell Immunopharma Appoints Lynn Seely as Interim CFO and Veronica Sanchez Bulis as Principal Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580621527","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580621527?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:31","pubTimestamp":1762176694,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Inc. has announced that Lynn Seely, M.D., the company's President and Chief Executive Officer, has been appointed as interim principal financial officer. Additionally, Veronica Sanchez Bulis, Vice President and Corporate Controller, has been named principal accounting officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL52srXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"2570001270","title":"Lyell Immunopharma Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2570001270","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570001270?lang=en_us&edition=fundamental","pubTime":"2025-09-26 19:32","pubTimestamp":1758886320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LYEL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 26, 2025 07:32 ET (11:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4505","LCID","BK4551","BK4555","BK4596","BK4539","LYEL","BK4139"],"gpt_icon":0},{"id":"2570000592","title":"Lyell Immunopharma initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2570000592","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570000592?lang=en_us&edition=fundamental","pubTime":"2025-09-26 19:15","pubTimestamp":1758885310,"startTime":"0","endTime":"0","summary":"Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $20 price target Lyell is a clinical-st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lyell-immunopharma-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lyell-immunopharma-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LYEL","BK4555","LCID","BK4551","BK4505","BK4099","BK4596","BK4139"],"gpt_icon":0},{"id":"2568362444","title":"Lyell Immunopharma Launches CFO Search After Newton Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2568362444","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568362444?lang=en_us&edition=fundamental","pubTime":"2025-09-17 05:23","pubTimestamp":1758057780,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma is searching for a new finance chief as Charles Newton will step down, effective Oct. 31.Newton will additionally step down as principal accounting officer, the biotechnology company said Tuesday.Lyell and Newton have entered an agreement under which he can provide consulting services through April 30, according to a Securities and Exchange Commission filing. The filing didn't specify why Newton chose to depart the company, though it noted there were no disagreements between the two parties.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"2568436356","title":"Lyell Immunopharma CFO Resignation Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=2568436356","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568436356?lang=en_us&edition=fundamental","pubTime":"2025-09-17 04:53","pubTimestamp":1758055985,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma ( ($LYEL) ) has issued an update. On September 15, 2025, Charles Newton announced his resignation as Chief Financial Officer of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lyell-immunopharma-cfo-resignation-announced?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lyell-immunopharma-cfo-resignation-announced?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LYEL","BK4505"],"gpt_icon":0},{"id":"2568543377","title":"Lyell Immunopharma Inc - Charles Newton Resigns as CFO of Lyell Immunopharma - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2568543377","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568543377?lang=en_us&edition=fundamental","pubTime":"2025-09-17 04:23","pubTimestamp":1758054223,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V30VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LYEL","BK4139","BK4539","BK4505"],"gpt_icon":0},{"id":"2564439538","title":"Lyell Immunopharma Begins Phase 3 Trial of LYL314 in Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2564439538","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564439538?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:30","pubTimestamp":1756902632,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma  said Wednesday it has started a phase 3 head-to-head trial of LYL314 in patients with relapsed or refractory large B-cell lymphoma.The study will evaluate LYL314 compared to liso-cel and axi-cel therapies in the second-line setting, the company said.Lyell said LYL314 is a dual-targeting CD19/CD20 CAR T-cell therapy that has received Regenerative Medicine Advanced Therapy and Fast Track designations from the US Food and Drug Administration.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4539","LYEL","BK4139"],"gpt_icon":0},{"id":"2564398442","title":"Lyell Immunopharma Initiates Phase 3 Trial for Innovative Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398442","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398442?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:00","pubTimestamp":1756900850,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Initiates Phase 3 Trial for Innovative Dual-Targeting CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma. Lyell Immunopharma Inc. has announced the initiation of a Phase 3 clinical trial, PiNACLE - H2H, to evaluate the efficacy of rondecabtagene autoleucel  compared to other approved CD19 CAR T-cell therapies in patients with relapsed or refractory large B-cell lymphoma. This trial marks the first head-to-head comparison of CAR T-cell therapies in this patient population. Ronde-cel is a next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to improve complete response rates and the duration of responses. The study will include patients receiving second-line treatment and also offers the option for outpatient administration based on the observed safety profile. Results of this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL8YFZmw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","NDAQ","BK4539","BK4585","LYEL","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2564981693","title":"Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head Car T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2564981693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564981693?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:00","pubTimestamp":1756900800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nTUA8B8WYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","LYEL","BK4539","BK4139"],"gpt_icon":0},{"id":"2564380753","title":"Lyell Immunopharma to Present at Morgan Stanley 23rd Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564380753","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564380753?lang=en_us&edition=fundamental","pubTime":"2025-09-03 04:05","pubTimestamp":1756843546,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Inc. , a late-stage clinical company developing next-generation CAR T-cell therapies for cancer patients, is scheduled to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The event will take place on Monday, September 8th, at 9:15 am Eastern Time. Members of Lyell's senior management team will present at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on September 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL5NR7xk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU0158827781.USD","LU2089283258.USD","LU2210149790.SGD","BK4539","LU1244550577.SGD","LU0795875086.SGD","LU0314104364.USD","LU1989772840.SGD","BK4504","LU1074936037.SGD","LU1720051108.HKD","LU0320765646.SGD","LU1668664300.SGD","LU2271345857.HKD","LU0912757837.SGD","LU0006306889.USD","BK4534","LU0098860793.USD","LU1244550221.USD","LU0106831901.USD","LU0106261372.USD","LU1989772923.USD","LU2133065610.SGD","BK4139","LU0267386448.USD","NDAQ","LU0225283273.USD","LU1548497426.USD","IE00BZ1G4Q59.USD","LYEL","LU0882574139.USD","BK4127","BK4516","BK4588","LU1162221912.USD","LU0158827948.USD","LU1244550494.USD","LU2357305700.SGD","LU2028103732.USD","BK4112","LU0971096721.USD","IE00BGHQF748.EUR","LU2023251221.USD","LU0234570918.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU1363072403.SGD","LU2089284900.SGD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2561400532","title":"Lyell Immunopharma's Chief Scientific Officer Gary K. Lee Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2561400532","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561400532?lang=en_us&edition=fundamental","pubTime":"2025-08-23 04:03","pubTimestamp":1755892981,"startTime":"0","endTime":"0","summary":"Gary K. Lee, the Chief Scientific Officer of Lyell Immunopharma Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL9yyrzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LYEL","BK4539","BK4139"],"gpt_icon":0},{"id":"2559371938","title":"CFO Charles W. Newton Reports Disposal of Lyell Immunopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2559371938","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559371938?lang=en_us&edition=fundamental","pubTime":"2025-08-14 09:06","pubTimestamp":1755133591,"startTime":"0","endTime":"0","summary":"Charles W. Newton, the Chief Financial Officer of Lyell Immunopharma Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLZDvBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LYEL","BK4539","BK4139"],"gpt_icon":0},{"id":"2559651621","title":"Lyell Immunopharma Reports Q2 2025 Net Loss of $42.7M, Decrease from $45.8M in Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2559651621","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559651621?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:09","pubTimestamp":1755029386,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on August 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1PJ44P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","BK4505","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LYEL","IE00BGHQF748.EUR","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","BK4112","BK4588","NDAQ"],"gpt_icon":0},{"id":"2559249196","title":"Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559249196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559249196?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029100,"startTime":"0","endTime":"0","summary":"Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132110/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LU0963586101.USD","CRS","IE00B19Z4B17.USD","BK4230","BK4539","BK4139","LU2065731478.USD","IE00B66KJ199.SGD","LYEL","BK4505","IE00B7SZL793.SGD","IE0031619046.USD","CAR","BK4006"],"gpt_icon":0},{"id":"2557317049","title":"Lyell Immunopharma Inc  expected to post a loss of $3.58 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557317049","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557317049?lang=en_us&edition=fundamental","pubTime":"2025-08-06 06:31","pubTimestamp":1754433081,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Inc  expected to post a loss of $3.58 a share - Earnings Preview Lyell Immunopharma Inc LYEL.OQ LYEL.O is expected to  show a fall in quarterly revenue when it reports  results on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nL8N3TX3TD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYEL"],"gpt_icon":0},{"id":"2555098414","title":"Lyell Immunopharma Inc. Files Initial Statement of Beneficial Ownership for ARCH Venture Fund XIII, L.P","url":"https://stock-news.laohu8.com/highlight/detail?id=2555098414","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555098414?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:24","pubTimestamp":1753838682,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma Inc. has filed an initial statement of beneficial ownership, identifying ARCH Venture Fund XIII, L.P. as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL17rRbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"2554762291","title":"Lyell Immunopharma Initiates Phase 3 Clinical Trial for LYL314 in Relapsed or Refractory Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2554762291","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554762291?lang=en_us&edition=fundamental","pubTime":"2025-07-25 20:06","pubTimestamp":1753445192,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc. has announced the initiation of two pivotal-stage clinical trials for its product candidate LYL314. The trials will focus on patients with large B-cell lymphoma  who have relapsed or are refractory to two or more lines of prior therapy. The company plans to submit a Biologics License Application for LYL314 later in 2027, following the expected data from the LYL314 PiNACLE pivotal trial. Additionally, Lyell is set to conduct a Phase 3 randomized controlled trial for LYL314 in the second-line setting for relapsed or refractory LBCL patients. Furthermore, the company intends to begin a clinical trial evaluating a new internally-developed CAR T-cell therapy targeting an undisclosed solid tumor. Results from these trials are anticipated in the future, with a clinical trial data update from LYL314 expected by the end of this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nNDL8lHkc7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4539","LYEL"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}